A peer-reviewed version of this preprint was published in PeerJ on 22 September 2015.

View the peer-reviewed version (peerj.com/articles/1229), which is the preferred citable publication unless you specifically need to cite this preprint.

https://doi.org/10.7717/peerj.1229
Novel epitopes identified from efflux pumps of *Mycobacterium tuberculosis* could induce cytotoxic T lymphocyte response

Mingxia Zhai, Fei Chen, Yuanyuan Zhao, Yahong Wu, Guodong Li, Yanfeng Gao, Yuanming Qi

Overcoming drug-resistance is one of the major challenges to control tuberculosis (TB). The up-regulation of efflux pumps is one common mechanism that leads to drug-resistance. Therefore, immunotherapy targeting these efflux pump antigens could be promising strategy to be combined with current chemotherapy. Considering that CD8+ cytotoxic T lymphocytes (CTLs) induced by antigenic peptides (epitopes) could elicit HLA-restricted anti-TB immune response, efflux pumps from classical ABC family (*Mycobacterium tuberculosis*, Mtb) were chosen as target antigens to identify CTL epitopes. HLA-A2 restricted candidate peptides from Rv2937, Rv2686c and Rv2687c of *Mycobacterium tuberculosis* were predicted, synthesized and tested. Five peptides could induce IFN-γ release and cytotoxic activity in PBMCs from HLA-A2+ PPD+ donors. Results from HLA-A2/Kb transgenic mice immunization assay suggested that four peptides Rv2937-p168, Rv2937-p266, Rv2686c-p151, and Rv2686c-p181 could induce significant CTL response *in vivo*. These results suggested that these novel epitopes could be used as immunotherapy candidates to TB drug-resistance.
Novel epitopes identified from efflux pumps of *Mycobacterium tuberculosis* could induce cytotoxic T lymphocyte response

Ming-xia Zhai, Fei Chen, Yuan-yuan Zhao, Ya-hong Wu, Guo-dong Li, Yan-feng Gao*, Yuan-ming Qi*

*School of Life Sciences, Zhengzhou University, Zhengzhou 450001, China*

*Correspondence: Prof. Yanfeng Gao or Yuan-ming Qi.*

School of Life Sciences, Zhengzhou University, 100 Kexue Road, Zhengzhou 450001, China

Tel.: +86-371-67781107; Fax: +86-371-67783235. E-mail: gaoyf@zzu.edu.cn; or qym@zzu.edu.cn
INTRODUCTION

Tuberculosis is a serious infection disease in developing countries, which is caused by *Mycobacterium tuberculosis* (Dye & Williams 2010). To date, the available strategies against tuberculosis mainly rely on chemotherapeutic regimens. However, with the emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug resistant tuberculosis (XDR-TB), it becomes more difficult to fight against tuberculosis. In addition to acquired drug resistance (Ramaswamy & Musser 1998), intrinsic drug resistance has been proved in *Mycobacterium tuberculosis* (Mtb) (De Rossi et al. 2006), in which active drug efflux pump does make contributions to drug resistance (Escribano et al. 2007; Spies et al. 2008).

As an intracellular pathogen living in macrophages, more and more evidence suggested the important role of cellular immunity in controlling the dissemination of Mtb. It has been proved that, in addition to CD4\(^+\) T cells, MHC class I restricted CD8\(^+\) T cells also play very important role in immune responses against Mtb. And large amounts of previous results have proved the role of CD8\(^+\) T cell-mediated immune responses in Mtb challenged mouse models, nonhuman primates as well as patients (D’Souza et al. 2000; Flynn & Chan 2001; Flynn et al. 1992; Lazarevic & Flynn 2002; Sousa et al. 2000).

Although a lot of researchers are trying to develop new vaccines, BCG is the only approved vaccine against tuberculosis, which efficacy in adults has been questioned (Black et al. 2002). Considering all these reasons mentioned above, we believed that it would be very worthy to identify HLA-A2 restricted cytotoxic T lymphocyte epitopes derived from drug efflux pump antigens of Mtb. It would help us to develop effective subunit vaccines against TB, especially XDR and MDR strains.

Classic ABC family is the most well-known efflux pump responsible for intrinsic drug resistance. It was shown that he over-expression of Rv2686c-Rv2687c-Rv2688c in *M.*
smegmatis increased the minimum inhibitory concentrations of ciprofloxacin (Pasca et al. 2004). And Rv2937 (drrB) behaved as a functional efflux pump referring to rifampin, tetracycline and erythromycin together with drrA (Choudhuri et al. 2002). Because that DrrA and Rv2688c have homology with some proteins in human, Rv2937, Rv2686c, and Rv2687c were chosen as target antigens to identify HLA-A2 restricted cytotoxic T lymphocyte epitopes.

Eight potential peptides derived from Rv2937, Rv2686c, and Rv2687c were predicted by using the online tools SYFPEITHI, BIMAS, and NetCTL. These peptides were synthesized and their ability to induce immune response was tested both in PBMCs of HLA-A2+ donors (in vitro) and HLA-A2/Kb transgenic mice (in vivo).

MATERIALS AND METHODS
Prediction and synthesis of candidate peptides
By using epitope prediction tools, BIMAS (http://bimas.dcr.nih.gov/molbio/hla_bind/) (Parker et al. 1994), SYFPEITHI (http://www.syfpeithi.de/Scripts/MHCServer.dll/EpitopePrediction.htm) (Rammensee et al. 1999), and NetCTL (http://www.cbs.dtu.dk/services/NetCTL/) (Larsen et al. 2007), potential HLA-A2-restricted T cell epitopes derived from Rv2937, Rv2686c, and Rv2687c were predicted. Peptides with relative high scores were synthesized by using standard solid phase Fmoc strategy. The peptides were purified by reverse phase-high performance liquid chromatography (RP-HPLC), and then their molecular weights were confirmed by electrospray ionization-mass spectrometry (ESI-MS). The HBV core antigen-derived T helper epitope (sequence128–140: TPPAYRPPNAPIL) was used to enhance the immune activity in the mice vaccination experiment (Milich et al. 1988; Vissers et al. 1999).

Blood samples, animals and cell lines
Whole blood was prepared from HLA-A2+ (PPD+ or PPD−) healthy donors. The HLA-A2.1/Kb transgenic mice were previously gifted by professor Xue-tao Cao (Second Military Medical University) (Vitiello et al. 1991). All mice at 8 to 12 weeks in the experiments were housed in a specific pathogen-free environment in our laboratory. The
sample collection from healthy donors and animal experiments were approved by the Ethics Committee of Zhengzhou University (No. 20120312). The human transporter associated with antigen processing (TAP) -deficient T2 cell line was kindly provided by professor Yu-zhang Wu (Third Military Medical University, China), and the cells were cultured in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS) and maintained at 37°C in an incubator with a humidified atmosphere containing 5% CO2.

**Generation of CTLs from HLA-A2 healthy donors**

The procedures of generation of CTLs in vitro were performed in accordance with the protocols described by our laboratory (Liu et al. 2012; Shi et al. 2013). Briefly, PBMCs were isolated from six HLA-A2+ PPD+ and an HLA-A2+ PPD- healthy donors with centrifugation at a Ficoll-Paque density gradient and then cultured in IMDM medium supplemented with 10% FBS under the condition of 37°C, 5% CO2 (Han et al. 2006). After 24h, PBMCs at the concentration of 1×10^6/ml were stimulated with the candidate peptides (10μg/ml) in the presence of 3μg/ml β2-m for 4h. The next day, human recombinant IL-2 (50 U/ml) and IL-7 (50 U/ml) were added. Once a week, these cells were re-stimulated same as the procedures above. Seven days after the third round of stimulation, the cytotoxic assay and ELISPOT assay were performed.

**Generation of CTLs from HLA-A2.1/Kb transgenic mice**

CTLs from HLA-A2.1/Kb transgenic mice were generated as previously described (Liu et al. 2012; Shi et al. 2013). Briefly, HLA-A2.1/Kb transgenic mice were grouped randomly, they were injected subcutaneously at the base of the tail with 100μg each peptide emulsified in incomplete Freund’s adjuvant (IFA) in the presence of 140μg of the T helper epitope every five days (Eguchi et al. 2006; Tourdot et al. 2000). On day 11, splenocytes of each mouse were separated and then re-stimulated with the corresponding peptide (10μg/ml) in vitro for another five days. Then, the LDH cytotoxicity and ELISPOT assays were employed.

**ELISPOT assay**

ELISPOT assay was performed according to the instruction of the commercial kit (Dakewe, China). Peptide-pulsed T2 cells (stimulator cells, 1×10^5), along with the induced CTLs (effector cells, 1×10^5), were seeded into an anti-human (or anti-mouse) IFN-γ antibody coated 96-well plate (Ding et al. 2009). After incubation for 16 h at 37°C, cells were removed and plates were processed. Spots were counted with a computer-assisted spot analyzer (Dakewe,
Cytotoxicity assay

Cytotoxic activity was tested by the non-radioactive cytotoxicity assay kit (Promega, US) at gradient E:T ratio according to the manufacturer's instruction. T2 cells were loaded with 10μg/ml peptide for 1h at 37°C as target cells. The effector cells were co-cultured with target cells (1×10^4/well) at various effector/target ratios for 5h at 37°C under 5% CO₂. The percentage of specific lysis of the target cells was determined according to the following formula. Percentage of specific lysis = [(experimental release – effector spontaneous release – target spontaneous release) / (target maximum release – target spontaneous release)] × 100.

Statistical analysis

All data were presented as means ± S.D. Comparisons between experimental groups and relevant controls were analyzed by Student's t test. P<0.05 was considered as a statistically significant difference.

RESULTS

Peptides selected as potential CTL epitopes

By using the on-line prediction tools, eight potential HLA-A2 restricted T cell epitopes were selected from the three candidate efflux pump antigens, Rv2937, Rv2686c, and Rv2687c. The peptides were synthesized and their molecular weights were confirmed by ESI-MS. (Table 1).

IFN-γ release ELISPOT assay in vitro

CTLs were induced from the PBMCs of six HLA-A2^+ PPD^+ and an HLA-A2^+ PPD^- healthy donors. IFN-γ release ELISPOT assay was employed to test the capacity of the eight peptides to induce CTL response. As shown in Fig. 1, among the six HLA-A2^+ PPD^+ donors, Rv2937-p168, Rv2937-p266, Rv2686c-p151, Rv2686c-p181, and Rv2686c-p184 could induce more frequent and potent CTL response, while all these peptides could only induce very weak response in the HLA-A2^+ PPD^- donor (Fig. S1).

In vitro cytotoxic activity of peptide-specific CTLs

Based on the results of the ELISPOT assay, Rv2937-p168, Rv2937-p266, Rv2686c-p151, Rv2686c-p181, and Rv2686c-p184 were selected to investigate whether the specific T cells
they induced could lyse target cells. In the cytotoxicity assay, peptide-pulsed T2 cells were considered as target cells, the effector cells were obtained from CTLs induced from PBMCs of HLA-A2^+ PPD^+ donor. As shown in Fig. 2, the specific lysis percentages of the CTLs induced by Rv2937-p168, Rv2937-p266, Rv2686c-p151, Rv2686c-p181, and Rv2686c-p184 from PBMCs of HLA-A2^+ PPD^+ healthy donors were increased gradiently from E/T ratio 12.5:1 to 50:1. However, after incubating with anti-HLA-A2 monoclonal antibody, the specific lysis rates of the CTLs derived from HLA-A2^+ PPD^+ were greatly reduced. These results indicated that these peptides could induce HLA-A2-restricted CTL response in PPD^+ healthy donor.

Cytotoxic T lymphocyte response in HLA-A2.1/K^b transgenic mice

HLA-A2.1/K^b transgenic mice immunization model is a widely used putative model to study the in vivo CTL activity of HLA-A2-restricted epitopes. Since Rv2937-p168, Rv2937-p266, Rv2686c-p151, Rv2686c-p181, and Rv2686c-p184 could induce good immune response in vitro, we then investigated whether these peptides could stimulate CTL response in HLA-A2.1/K^b transgenic mice. After immunization of the candidate peptides with Th epitope and IFA adjuvant, the splenocytes were isolated and stimulated with the corresponding peptide in vitro for another five days. IFN-γ release ELISPOT assay and LDH cytotoxicity assay were performed. As shown in Fig. 3, all of the five peptides showed more potent activity to induce IFN-γ release than the negative control group.

The cytotoxic activity of these splenocytes was also measured by an LDH cytotoxicity assay. Peptide-loaded T2 cells were served as target cells and the effector/target ratios were 20:1, 40:1, and 80:1. As shown in Fig. 4, at the E:T ratio of 80:1, the CTLs induced by Rv2937-p168, Rv2937-p266, Rv2686c-p151, and Rv2686c-p181 could significantly kill the target cells. To our surprise, although Rv2686c-p184 could induce the most potent IFN-γ release activity in PBMCs of HLA-A2^+ PPD^+ donors, it could not induce CTLs with killing effects in HLA-A2.1/K^b transgenic mice.

DISCUSSION

Tuberculosis is considered as a major public health concern worldwide because of the high mortality and morbidity associated with it. And as reported, the emergence of XDR-TB and MDR-TB forced patients having fewer options for treatment and risking higher mortalities, especially in HIV/TB co-infected ones (Principi & Esposito 2015). Development of novel therapeutic vaccines provides a promising strategy to combine with chemotherapy.
Accumulating data showed that subunit vaccine containing peptide or protein antigens could exhibit protective activity and very good safety (Ivanyi 2014).

HLA-A2 is one of the most common supertypes of human leukocyte antigen particularly in Asian with an estimated frequency of nearly 50% (Mehra et al. 2001), and cell-mediated immunity to Mtb is believed important to control the latent Mtb infection, therefore, identification of HLA-A2 restricted cytotoxic T lymphocyte epitopes derived from efflux pump antigens could be helpful to develop vaccines against drug-resistant TB caused by intrinsic drug efflux. Recently, most researchers who hammer at identification of CTL epitopes of Mtb antigens focused their work on secretary protein, such as ESAT-6(Lalvani et al. 1998), 19-kDa lipoprotein(Mohagheghpour et al. 1998), Ag85B(Geluk et al. 2000), 16-kDa antigen(Caccamo et al. 2002) and MPT51(Suzuki et al. 2004), and so on. We also identified such kind of epitopes from antigen CFP21 and RD region (Chen et al. 2012; Lv et al. 2010). Furthermore, we firstly reported that efflux pumps could also be considered as target antigens for TB immunotherapy and found that Rv1410c could serve as a candidate to the vaccine design against drug-resistant Mtb (Zhu et al. 2011). Then we screened classical efflux pump family members in the genome of TB to find more promising target antigens. As shown in the present study, we found that epitopes, Rv2937-p168, Rv2937-p266, Rv2937-p168, Rv2686c-p181, and Rv2686c-p184 identified from ABC family members, elicited good capacity to induce CTL response in HLA-A2\(^{+}\) PPD\(^{+}\) healthy donors and/or HLA-A2.1/K\(^{b}\) transgenic mice. Work is still need to be done to identify more promising antigens related to drug-resistant Mtb. We are now also working on extrinsic in TB. Hopefully, we can combine all these epitopes derived from secretary and drug-resistant antigens to develop multi-valent subunit vaccines.

As we all known, early diagnosis of TB is fundamental for tuberculosis control. In the last decade, ELISPOT assay in the TB diagnosis is considered to have high specificity and sensitivity (Lalvani & Pareek 2010; Milotic et al. 2011). Most of the five candidate peptides showed good activity among the six HLA-A2\(^{+}\) PPD\(^{+}\) healthy donors, but not in HLA-A2\(^{+}\) PPD\(^{-}\). Although we do not know whether these PPD\(^{-}\) donors have drug-resistant Mtb infection, the results indicated that these epitopes might also be used as TB diagnosis.

In the present study, we used so called ‘reversal immunology’ strategy to predict antigen epitopes by using on-line tools instead of time-consuming overlapping peptides method, which was very efficient. However, using just one computational algorithm to predict CTL epitopes may lead to large amounts of false positive and false negatives. So we used epitope prediction tool NetCTL combined with the widely used BIMAS and SYFPEITHI databases.
NetCTL integrates prediction of binding affinity, transporter of antigenic peptide efficiency and proteasomal cleavage (Larsen et al. 2007), SYFPEITHI is a motif-matrix-based prediction method for MHC binding prediction (Rammensee et al. 1999) and BIMAS is based on peptide/MHC complex half-life (Parker et al. 1994). Our results suggested that this strategy could be very efficient and successful.

CONCLUSIONS

In conclusion, we have identified five HLA-A2 restricted cytotoxic T lymphocyte epitopes derived from drug efflux pump antigens of Mycobacterium tuberculosis. The epitopes Rv2937-p168, Rv2937-p266, Rv2686c-p151, Rv2686c-p181, and Rv2686c-p184 showed good capacity to induce CTL response in HLA-A2\textsuperscript{+} PPD\textsuperscript{+} donors. Except Rv2686c-p184, other epitopes could also elicit CTL response when immunized in HLA-A2.1/K\textsuperscript{b} transgenic mice. These epitopes could serve as candidates for TB diagnosis and immunotherapy.

REFERENCES


Figure 1. IFN-γ release ELISPOT assay by CTLs induced from PBMCs of HLA-A2+ PPD+ donors. Each peptide was tested by using the samples from the same group of six donors. PBMCs from healthy donors were separated and stimulated once a week with synthetic peptides and IL-2 for three rounds.
Figure 2. Specific lysis of T2 cells loaded with synthetic peptides by the CTLs generated from PBMCs of HLA-A2+ PPD+ donors. (A-B) The effector cells were obtained from CTLs induced from PBMCs of HLA-A2+ PPD+ donors. (C) The HLA-A2 molecules on the T2 cells surface were blocked by anti-HLA-A2 monoclonal antibody.
Figure 3. IFN-γ release ELISPOT assay of the splenocytes from the immunized HLA-A2.1/Kb transgenic mice. HLA-A2.1/Kb transgenic mice were immunized with 100μg each peptide emulsified in incomplete Freund’s adjuvant (IFA) in the presence of 140μg of the T helper epitope every five days for three times.
Figure 4. Specific lysis of T2 cells loaded with synthetic peptides by the CTLs generated from the immunized HLA-A2.1/Kb transgenic mice (n=5). The data from each peptide immunized group were compared with the Th epitope alone negative control.
Table 1. HLA-A2 CTL epitopes predicted from efflux pumps of *Mycobacterium tuberculosis*

<table>
<thead>
<tr>
<th>Antigen</th>
<th>Position</th>
<th>Sequence</th>
<th>SYFPEITHI</th>
<th>NetCTL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rv2937</td>
<td>168</td>
<td>YIVGFCLLV</td>
<td>24</td>
<td>1.2629</td>
</tr>
<tr>
<td></td>
<td>262</td>
<td>VMAPTLTWL</td>
<td>27</td>
<td>1.2098</td>
</tr>
<tr>
<td></td>
<td>266</td>
<td>TLTWLFAFV</td>
<td>22</td>
<td>1.1149</td>
</tr>
<tr>
<td>Rv2686c</td>
<td>151</td>
<td>GLVAGLSAV</td>
<td>28</td>
<td>0.9644</td>
</tr>
<tr>
<td></td>
<td>181</td>
<td>ALGMLIAGL</td>
<td>30</td>
<td>0.9898</td>
</tr>
<tr>
<td></td>
<td>184</td>
<td>MLIAGLPCL</td>
<td>29</td>
<td>1.3358</td>
</tr>
<tr>
<td>Rv2687c</td>
<td>89</td>
<td>YLAAKLTVL</td>
<td>29</td>
<td>1.3019</td>
</tr>
<tr>
<td></td>
<td>151</td>
<td>FLAAVIPLA</td>
<td>22</td>
<td>1.2362</td>
</tr>
</tbody>
</table>